Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:39:37 EDT Sat 04 May 2024
Enter Symbol
or Name
USA
CA



News for U:PTN from 2023-05-04 to 2024-05-03 - 35 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-02 07:30U:PTNNews ReleasePalatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
2024-04-30 07:30U:PTNNews ReleasePalatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
2024-04-08 07:30U:PTNNews ReleasePalatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
2024-02-28 07:30U:PTNNews ReleasePalatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
2024-02-15 07:30U:PTNNews ReleasePalatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
2024-02-09 07:30U:PTNNews ReleasePalatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024
2024-02-05 07:30U:PTNNews ReleasePalatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
2024-02-01 16:00U:PTNNews ReleasePalatin Announces Closing of $10 Million Registered Direct Offering
2024-01-30 08:00U:PTNNews ReleasePalatin Announces $10 Million Registered Direct Offering
2024-01-08 10:33U:PTNNews ReleasePalatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024
2024-01-03 08:00U:PTNNews ReleaseCosette Pharmaceuticals Acquires Vyleesi ‚ ® (Bremelanotide Injection) from Palatin Technologies Inc.
2023-12-20 07:30U:PTNNews ReleasePalatin Completes Sale of Vyleesi ‚ ® to Cosette Pharmaceuticals for up to $171 Million
2023-12-18 16:15U:PTNNews ReleasePalatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
2023-11-14 07:30U:PTNNews ReleasePalatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
2023-11-09 07:30U:PTNNews ReleasePalatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023
2023-10-24 16:50U:PTNNews ReleasePalatin Announces Closing of $5 Million Registered Direct Offering
2023-10-23 07:30U:PTNNews ReleasePalatin Announces $5 Million Registered Direct Offering
2023-10-19 07:30U:PTNNews ReleasePalatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi ‚ ® Product Revenue Results
2023-10-18 07:30U:PTNNews ReleasePalatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients
2023-10-16 07:30U:PTNNews ReleasePalatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis Treatment
2023-10-13 16:15U:PTNNews ReleasePalatin Receives Notice of Non-Compliance from NYSE American
2023-09-28 07:30U:PTNNews ReleasePalatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate Update
2023-09-22 16:00U:PTNNews ReleasePalatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023
2023-09-07 16:00U:PTNNews ReleasePalatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-09-07 07:30U:PTNNews ReleasePalatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643 For the Treatment of Patients with Dry Eye Disease
2023-08-10 07:30U:PTNNews ReleasePalatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment
2023-08-08 07:30U:PTNNews ReleasePalatin's Vyleesi ‚ ® Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study
2023-08-07 07:30U:PTNNews ReleasePalatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth ¢ „ ¢ for Vyleesi ‚ ®
2023-08-04 07:30U:PTNNews ReleasePalatin to Participate in Canaccord Genuity's 43rd Annual Growth Conference
2023-07-11 07:30U:PTNNews ReleasePalatin Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi ‚ ® Product Revenue Results
2023-05-30 07:30U:PTNNews ReleasePalatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference
2023-05-16 07:30U:PTNNews ReleasePalatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
2023-05-11 16:15U:PTNNews ReleasePalatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023
2023-05-09 07:30U:PTNNews ReleasePalatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference
2023-05-08 16:04U:PTNNews ReleasePalatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar